In today's Just The Facts...
Race Oncology has unveiled new preclinical data at the ESMO Congress in Berlin. The company's (E,E)-bisantrene not only boosts tumour-killing power when paired with doxorubicin, but also protects the heart.
Astral Resources has signed a Letter of Intent with Mineral Mining Services to fully fund development of its Think Big gold deposit near Kalgoorlie. The deal provides a clear, low-risk path to early gold production and cash flow, while preserving value for shareholders.
Orthocell is strengthening its regenerative medicine portfolio, lifting its stake in Marine Biomedical to 12% and securing global distribution rights to PearlBone™ — a next-generation bone substitute made from WA pearl shells and targeting the US$1.6 billion bone repair market.
#ASX #Biotech #GoldMining #MedTech #Investing #Australia #MarketUpdate